Molecular Pathways: CDK4 Inhibitors for Cancer TherapyDICKSON, Mark A.Clinical cancer research (Print). 2014, Vol 20, Num 13, pp 3379-3383, issn 1078-0432, 5 p.Article

Absence of R24C mutation of the CDK4 gene in leukemias and solid tumorsMORI, Naoki; RONG YANG; KAWAMATA, Norihiko et al.International journal of hematology. 2003, Vol 77, Num 3, pp 259-262, issn 0925-5710, 4 p.Article

Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomasBACHMANN, Ingeborg M; STRAUME, Oddbjørn; AKSLEN, Lars A et al.International journal of oncology. 2004, Vol 25, Num 6, pp 1559-1565, issn 1019-6439, 7 p.Article

Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidizationMUNTEAN, Andrew G; LIYAN PANG; PONCZ, Mortimer et al.Blood. 2007, Vol 109, Num 12, pp 5199-5207, issn 0006-4971, 9 p.Article

Cyclin D2-Cyclin-Dependent Kinase 4/6 Is Required for Efficient Proliferation and Tumorigenesis following Apc LossCOLE, Alicia M; MYANT, Kevin; SANSOM, Owen J et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 20, pp 8149-8158, issn 0008-5472, 10 p.Article

Expression of p16^Ink4a compensates for p18^Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissuesRAMSEY, Matthew R; KRISHNAMURTHY, Janakiraman; PEI, Xin-Hai et al.Cancer research (Baltimore). 2007, Vol 67, Num 10, pp 4732-4741, issn 0008-5472, 10 p.Article

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSHEPPARD, Karen E; MCARTHUR, Grant A.Clinical cancer research (Print). 2013, Vol 19, Num 19, pp 5320-5328, issn 1078-0432, 9 p.Article

Pharmacologic inhibition of CDK4/6 : mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemiaLISHENG WANG; JIE WANG; BLASER, Bradley W et al.Blood. 2007, Vol 110, Num 6, pp 2075-2083, issn 0006-4971, 9 p.Article

Role of cdk4, p16^INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomasGHAZIZADEH, Mohammad; ENJING JIN; SHIMIZU, Hajime et al.Respiration (Basel). 2005, Vol 72, Num 1, pp 68-73, issn 0025-7931, 6 p.Article

Cdk2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesisMARIAS, Everardo; KIM, Yongbaek; MILIANI DE MARVAL, Paula L et al.Cancer research (Baltimore). 2007, Vol 67, Num 20, pp 9713-9720, issn 0008-5472, 8 p.Article

Dedifferentiated liposarcoma with rhabdomyoblastic differentiationSHIMADA, Shio; ISHIZAWA, Takashi; ISHIZAWA, Keisuke et al.Virchows Archiv. 2005, Vol 447, Num 5, pp 835-841, issn 0945-6317, 7 p.Article

Spontaneous Regression of Human Cancer Cells In Vitro: Potential Role of Disruption of Cdkl/Cdk4 Co-expressionWARENIUS, Hilmar; KYRITSI, Leto; GRIERSON, Ian et al.Anticancer research. 2009, Vol 29, Num 6, pp 1933-1941, issn 0250-7005, 9 p.Article

Clinical and Biological Significance of CDK4 Amplification in Well-Differentiated and Dedifferentiated LiposarcomasITALIANO, Antoine; BIANCHINI, Laurence; CHIBON, Frédéric et al.Clinical cancer research (Print). 2009, Vol 15, Num 18, pp 5696-5703, issn 1078-0432, 8 p.Article

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced CancerFLAHERTY, Keith T; LORUSSO, Patricia M; DEMICHELE, Angela et al.Clinical cancer research (Print). 2012, Vol 18, Num 2, pp 568-576, issn 1078-0432, 9 p.Article

A CDKN2A mutation in familial melanoma that abrogates binding of p16^INK4a to cdk4 but not CDK6JONES, Rebecca; RUAS, Margarida; GREGORY, Fiona et al.Cancer research (Baltimore). 2007, Vol 67, Num 19, pp 9134-9141, issn 0008-5472, 8 p.Article

Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivoJING LIN; YAN, Xiao-Jun; CHEN, Hai-Min et al.Cancer chemotherapy and pharmacology. 2007, Vol 59, Num 4, pp 439-445, issn 0344-5704, 7 p.Article

Characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant miceMETTUS, Richard V; RANE, Sushil G.Oncogene (Basingstoke). 2003, Vol 22, Num 52, pp 8413-8421, issn 0950-9232, 9 p.Article

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated LiposarcomaDICKSON, Mark A; TAP, William D; USTOYEV, Yelena et al.Journal of clinical oncology. 2013, Vol 31, Num 16, pp 2024-2028, issn 0732-183X, 5 p.Article

Attenuation of the Retinoblastoma Pathway in Pancreatic Neuroendocrine Tumors Due to Increased Cdk4/Cdk6TANG, Laura H; CONTRACTOR, Tanupriya; CLAUSEN, Richard et al.Clinical cancer research (Print). 2012, Vol 18, Num 17, pp 4612-4620, issn 1078-0432, 9 p.Article

Expression of CDK4 or CDK2 in Mouse Oral Cavity Is Retained in Adult Pituitary with Distinct Effects on TumorigenesisMACIAS, Everardo; MILIANI DE MARVAL, Paula L; SENDEROWICZ, Adrian et al.Cancer research (Baltimore). 2008, Vol 68, Num 1, pp 162-171, issn 0008-5472, 10 p.Article

Cyclin-dependent kinase 4 expression is essential for neu-lnduced breast tumorigenesisREDDY, Haritha K. D. L; METTUS, Richard V; RANE, Sushil G et al.Cancer research (Baltimore). 2005, Vol 65, Num 22, pp 10174-10178, issn 0008-5472, 5 p.Article

Mutational effects on the p16^INK4a tumor suppressor proteinRONG YANG; GOMBART, A. F; SERRANO, M et al.Cancer research (Baltimore). 1995, Vol 55, Num 12, pp 2503-2506, issn 0008-5472Article

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in NeuroblastomaRADER, Julieann; RUSSELL, Mike R; SUNKYU KIM et al.Clinical cancer research (Print). 2013, Vol 19, Num 22, pp 6173-6182, issn 1078-0432, 10 p.Article

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphomaLEONARD, John P; LACASCE, Ann S; NEUBERG, Donna S et al.Blood. 2012, Vol 119, Num 20, pp 4597-4607, issn 0006-4971, 11 p.Article

Cyclin D1 and Cdk4 Mediate Development of Neurologically Destructive OligodendrogliomaCIZNADIJA, Daniel; YUHUI LIU; PYONTECK, Stephanie M et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 19, pp 6174-6183, issn 0008-5472, 10 p.Article